From discovery to impact: Five novel drug assets that showcase India's innovation potential

For decades, India's pharmaceutical reputation has rested on scale. The country's exports exceeded US$30.5 billion in FY 2024–25, and that scale has done something the world rarely acknowledges enough: it has kept life-saving medicines within reach of millions who would otherwise go without. This has earned India the title of "the world's pharmacy." While that chapter is far from closed, a new one has quietly begun.

Over the past decade, a set of novel drug assets has emerged from Indian labs and boardrooms, and together they mark a shift in the country's life sciences sector. These assets differ in platform, therapeutic area and business model, but they share a common origin: they were conceived, discovered and developed in India. Taken together, they trace the arc of an ecosystem moving from scientific capability to scientific ownership.

For investors, that distinction is the whole story. A single breakthrough rarely builds an industry. What builds an industry is repetition: multiple, independent proof points that innovation here is not a fluke but a pattern. India's life sciences sector is beginning to show exactly that pattern.

A new phase of pharmaceutical innovation

Start with Zydus and its work on Saroglitazar and Desidustat. Read together, these two molecules say something larger about where Indian pharma now stands: companies here can discover, develop and commercialise original therapies, not just manufacture someone else's.

Indigenous innovation has moved out of the research paper and into the clinic, a meaningful evolution for an industry long defined by generics.

ImmunoACT's NexCAR19 tells a parallel story, one where academic science becomes a commercially viable therapy. Advanced cell therapies have historically carried price tags that placed them out of reach for most patients, weighed down by the cost of treatment and the infrastructure behind it. NexCAR19 proves that frontier science can be re-engineered for affordability, and in doing so, it stakes out India's real advantage: not imitation, but reinvention at scale.

Glenmark's approach adds another dimension. Its global licensing deals for novel biologics including ISB 2001, ISB 880, ISB 830, make the case that a biotech company doesn't need to commercialize every asset itself to create value from it. Intellectual property, on its own, is now an exportable asset. Licensing lets a company monetise the science while leaning on global partners for late-stage development and market access. Each such deal is also a vote of confidence from international partners in the calibre of science coming out of India.

A third shift is underway at companies like Peptris Technologies, where artificial intelligence is starting to rewrite the economics of drug discovery. Drug development has always been an expensive, attrition-heavy business. AI won't erase that risk, but by sharpening target identification and molecule design, it stands to make the process far more capital-efficient, and global investors are taking notice. Given India's depth in engineering and computational science, the country is well positioned to lead in this next generation of discovery, not merely participate in it.

And then there is Wockhardt, whose work in novel antibiotics is a reminder that the most valuable innovation often addresses the problem no one else wants to touch. Antimicrobial resistance is fast becoming one of this century's defining health threats: a 2025 World Health Organisation report found that nearly one in six lab-confirmed bacterial infections worldwide in 2023 were already resistant to treatment. Yet antibiotic discovery remains one of the most underfunded corners of pharmaceutical research, precisely because the economics rarely favour it. Against that backdrop, the development of Nafithromycin and the recent global regulatory recognition of Zaynich show that Indian companies are stepping into the gap between scientific need and commercial incentive and delivering solutions that extend well beyond India's own borders.

Seen individually, these are five good stories, but together, they are something more significant.

The next phase of India's innovation journey

No two of these companies got here the same way. Some built in-house research capability from the ground up. Others leaned on AI or on global licensing partnerships. That diversity is not a weakness to explain away; it is the strongest signal of the variety India possesses. Mature innovation ecosystems are never built on a single technology or a single business model; they are built when multiple approaches thrive side by side, and that is exactly what is starting to take shape here.

The ingredients for sustained momentum are largely in place: a deep bench of scientific talent, a growing biotech startup base, real clinical research capability, an expanding set of global partnerships, and a policy environment that is finally catching up. Investor appetite reflects this shift; India's biotech sector drew $4.6 billion across 208 deals in 2025. The next test is whether that capital can go the distance: whether it is patient enough to fund science through the uncertainty that scientific discovery inevitably demands.

The question is no longer whether India can produce breakthrough therapies. The real question is whether it can make that the norm rather than the exception. If it does, India's contribution to global health will no longer be measured only in the medicines it manufactures, but in the science it originates.

For investors watching this space, the signal is clear: India's pharmaceutical sector is no longer just the world's supplier. It is becoming its competitor, and building the innovation ecosystem to prove it.

The author is the co-founder & general partner of Healthkois.

The opinions expressed in this article are those of the author and do not purport to reflect the opinions or views of THE WEEK.